The application of human serum albumin in liver cirrhosis and its complications

Yaxin LI; Huiguo DING

doi:10.12449/JCH250303

Volume 41 Issue 3

Mar. 2025

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2025 > 41(3): 409-414

PDF( 607 KB)

The application of human serum albumin in liver cirrhosis and its complications

DOI: 10.12449/JCH250303

Yaxin LI,
Huiguo DING^{,
,}

Department of Hepatology and Gastroenterology，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Capital Medical Development and Research Fund (2022-1-2181)

More Information

Corresponding author: DING Huiguo， dinghuiguo@ccmu.edu.cn （ORCID： 0000-0002-8716-4926）
Received Date: 2024-10-08
Accepted Date: 2025-01-15
Published Date: 2025-03-25

Abstract

Abstract

Albumin is synthesized in the liver， and in case of severe liver injury， albumin synthesis is reduced with structural alterations （such as an increase in methylation and glycosylation）， leading to a significant reduction in effective albumin in circulation. Albumin not only maintains plasma oncotic pressure， but also has the functions of antioxidation， anti-inflammation， immunomodulation， and transport. Current guidelines recommend the short-term application of human serum albumin in the treatment of large-volume paracentesis， hepatorenal syndrome， and spontaneous bacterial peritonitis in patients with liver cirrhosis， as it is shown that human serum albumin can help to reduce mortality. In addition， human serum albumin may improve the prognosis of cirrhotic patients with hyponatremia， non-SBP infections， and hepatic encephalopathy. However， there are still controversies over the application of human serum albumin in liver cirrhosis and related complications in terms of optimal dose and long-term efficacy.
- Albumins,
- Liver Cirrhosis,
- Ascites,
- Hepatorenal Syndrome,
- Hepatic Encephalopathy,
- Therapeutics

FullText(HTML)

References(51)

References

[1]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398( 10308): 1359- 1376. DOI: 10.1016/s0140-6736(21)01374-x.
[2]	de MATTOS ÂZ, SIMONETTO DA, TERRA C, et al. Albumin administration in patients with cirrhosis: Current role and novel perspectives[J]. World J Gastroenterol, 2022, 28( 33): 4773- 4786. DOI: 10.3748/wjg.v28.i33.4773.
[3]	POMPILI E, ZACCHERINI G, BALDASSARRE M, et al. Albumin administration in internal medicine: A journey between effectiveness and futility[J]. Eur J Intern Med, 2023, 117: 28- 37. DOI: 10.1016/j.ejim.2023.07.003.
[4]	BAI ZH, MÉNDEZ-SÁNCHEZ N, ROMEIRO FG, et al. Use of albumin infusion for cirrhosis-related complications: An international position statement[J]. JHEP Rep, 2023, 5( 8): 100785. DOI: 10.1016/j.jhepr.2023.100785.
[5]	ANDERSEN JT, DALHUS B, VIUFF D, et al. Extending serum half-life of albumin by engineering neonatal Fc receptor(FcRn) binding[J]. J Biol Chem, 2014, 289( 19): 13492- 13502. DOI: 10.1074/jbc.M114.549832.
[6]	WU NJ, LIU TT, TIAN MM, et al. Albumin, an interesting and functionally diverse protein, varies from‘native’ to‘effective’(Review)[J]. Mol Med Rep, 2024, 29( 2): 24. DOI: 10.3892/mmr.2023.13147.
[7]	GARCIA-MARTINEZ R, CARACENI P, BERNARDI M, et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications[J]. Hepatology, 2013, 58( 5): 1836- 1846. DOI: 10.1002/hep.26338.
[8]	CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin lipidomics reveals meaningful compositional changes in advanced cirrhosis and its potential to promote inflammation resolution[J]. Hepatol Commun, 2022, 6( 6): 1443- 1456. DOI: 10.1002/hep4.1893.
[9]	CASULLERAS M, FLORES-COSTA R, DURAN-GÜELL M, et al. Albumin internalizes and inhibits endosomal TLR signaling in leukocytes from patients with decompensated cirrhosis[J]. Sci Transl Med, 2020, 12( 566): eaax5135. DOI: 10.1126/scitranslmed.aax5135.
[10]	BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69( 6): 1127- 1138. DOI: 10.1136/gutjnl-2019-318843.
[11]	AITHAL GP, PALANIYAPPAN N, CHINA L, et al. Guidelines on the management of ascites in cirrhosis[J]. Gut, 2021, 70( 1): 9- 29. DOI: 10.1136/gutjnl-2020-321790.
[12]	SIMONETTI RG, PERRICONE G, NIKOLOVA D, et al. Plasma expanders for people with cirrhosis and large ascites treated with abdominal paracentesis[J]. Cochrane Database Syst Rev, 2019, 6( 6): CD004039. DOI: 10.1002/14651858.CD004039.pub2.
[13]	SHRESTHA DB, BUDHATHOKI P, SEDHAI YR, et al. Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 26: 100547. DOI: 10.1016/j.aohep.2021.100547.
[14]	BAI ZH, WANG L, WANG R, et al. Use of human albumin infusion in cirrhotic patients: A systematic review and meta-analysis of randomized controlled trials[J]. Hepatol Int, 2022, 16( 6): 1468- 1483. DOI: 10.1007/s12072-022-10374-z.
[15]	XU XY, DING HG, JIA JD, et al. Chinese guidelines on the management of ascites in cirrhosis: Chinese Society of Hepatology, Chinese Medical Association[J]. Hepatol Int, 2024, 18( 4): 1071- 1089. DOI: 10.1007/s12072-024-10697-z.
[16]	ALESSANDRIA C, ELIA C, MEZZABOTTA L, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: Standard vs half albumin doses. A prospective, randomized, unblinded pilot study[J]. Dig Liver Dis, 2011, 43( 11): 881- 886. DOI: 10.1016/j.dld.2011.06.001.
[17]	CHINA L, FREEMANTLE N, FORREST E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis[J]. N Engl J Med, 2021, 384( 9): 808- 817. DOI: 10.1056/NEJMoa2022166.
[18]	ARORA V, VIJAYARAGHAVAN R, MAIWALL R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure[J]. Hepatology, 2020, 72( 3): 1043- 1055. DOI: 10.1002/hep.31071.
[19]	TORP N, ISRAELSEN M, COENRAAD M, et al. Personalised human albumin in patients with cirrhosis and ascites: Design and rationale for the ALB-TRIAL—a randomised clinical biomarker validation trial[J]. BMJ Open, 2024, 14( 2): e079309. DOI: 10.1136/bmjopen-2023-079309.
[20]	MATTOS AA, WILTGEN D, JOTZ RF, et al. Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis[J]. Ann Hepatol, 2020, 19( 5): 451- 457. DOI: 10.1016/j.aohep.2020.04.010.
[21]	PAINE CH, BIGGINS SW, PICHLER RH. Albumin in cirrhosis: More than a colloid[J]. Curr Treat Options Gastroenterol, 2019, 17( 2): 231- 243. DOI: 10.1007/s11938-019-00227-4.
[22]	SORT P, NAVASA M, ARROYO V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis[J]. N Engl J Med, 1999, 341( 6): 403- 409. DOI: 10.1056/NEJM199908053410603.
[23]	KAR PS, VENISHETTY S, LAROIA ST, et al. Tolerance of standard dose albumin infused over 6 hrs for treatment of spontaneous bacterial peritonitis-a randomized controlled trial[J]. Indian J Gastroenterol, 2023, 42( 4): 505- 516. DOI: 10.1007/s12664-023-01389-x.
[24]	GARCIA-TSAO G, ABRALDES JG, RICH NE, et al. AGA clinical practice update on the use of vasoactive drugs and intravenous albumin in cirrhosis: Expert review[J]. Gastroenterology, 2024, 166( 1): 202- 210. DOI: 10.1053/j.gastro.2023.10.016.
[25]	NADIM MK, KELLUM JA, FORNI L, et al. Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative(ADQI) and International Club of Ascites(ICA) joint multidisciplinary consensus meeting[J]. J Hepatol, 2024, 81( 1): 163- 183. DOI: 10.1016/j.jhep.2024.03.031.
[26]	ORTEGA R, GINÈS P, URIZ J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study[J]. Hepatology, 2002, 36( 4 Pt 1): 941- 948. DOI: 10.1053/jhep.2002.35819.
[27]	BAI ZH, GUO XZ, TACKE F, et al. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819881302. DOI: 10.1177/1756284819881302.
[28]	IS B, BOMBASSARO IZ, TOVO CV, et al. Albumin in the management of hepatic encephalopathy: A systematic review and meta-analysis[J]. Ann Hepatol, 2021, 26: 100541. DOI: 10.1016/j.aohep.2021.100541.
[29]	TEH KB, LOO JH, TAM YC, et al. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis[J]. Dig Liver Dis, 2021, 53( 7): 817- 823. DOI: 10.1016/j.dld.2021.04.030.
[30]	SHARMA BC, SINGH J, SRIVASTAVA S, et al. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy[J]. J Gastroenterol Hepatol, 2017, 32( 6): 1234- 1239. DOI: 10.1111/jgh.13666.
[31]	FAGAN A, GAVIS EA, GALLAGHER ML, et al. A double-blind randomized placebo-controlled trial of albumin in outpatients with hepatic encephalopathy: HEAL study[J]. J Hepatol, 2023, 78( 2): 312- 321. DOI: 10.1016/j.jhep.2022.09.009.
[32]	BAJAJ JS, TANDON P, O’LEARY JG, et al. The impact of albumin use on resolution of hyponatremia in hospitalized patients with cirrhosis[J]. Am J Gastroenterol, 2018, 113( 9): 1339. DOI: 10.1038/s41395-018-0119-3.
[33]	BAI ZH, XU WT, CHAI L, et al. Effects of short-term human albumin infusion for the prevention and treatment of hyponatremia in patients with liver cirrhosis[J]. J Clin Med, 2022, 12( 1): 107. DOI: 10.3390/jcm12010107.
[34]	CHINA L, FREEMANTLE N, FORREST E, et al. Targeted albumin therapy does not improve short-term outcome in hyponatremic patients hospitalized with complications of cirrhosis: Data from the ATTIRE trial[J]. Am J Gastroenterol, 2021, 116( 11): 2292- 2295. DOI: 10.14309/ajg.0000000000001488.
[35]	FERNÁNDEZ J, CLÀRIA J, AMORÓS A, et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology, 2019, 157( 1): 149- 162. DOI: 10.1053/j.gastro.2019.03.021.
[36]	FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18( 4): 963- 973. e 14. DOI: 10.1016/j.cgh.2019.07.055.
[37]	WONG YJ, QIU TY, TAM YC, et al. Efficacy and Safety of IV albumin for non-spontaneous bacterial peritonitis infection among patients with cirrhosis: A systematic review and meta-analysis[J]. Dig Liver Dis, 2020, 52( 10): 1137- 1142. DOI: 10.1016/j.dld.2020.05.047.
[38]	MAIWALL R, KUMAR A, PASUPULETI SSR, et al. A randomized-controlled trial comparing 20% albumin to plasmalyte in patients with cirrhosis and sepsis-induced hypotension[ALPS trial][J]. J Hepatol, 2022, 77( 3): 670- 682. DOI: 10.1016/j.jhep.2022.03.043.
[39]	CALLUM J, SKUBAS NJ, BATHLA A, et al. Use of intravenous albumin: A guideline from the international collaboration for transfusion medicine guidelines[J]. Chest, 2024, 166( 2): 321- 338. DOI: 10.1016/j.chest.2024.02.049.
[40]	DI PASCOLI M, FASOLATO S, PIANO S, et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites[J]. Liver Int, 2019, 39( 1): 98- 105. DOI: 10.1111/liv.13968.
[41]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
[42]	WIEDERMANN CJ. Controversies surrounding albumin use in sepsis: Lessons from cirrhosis[J]. Int J Mol Sci, 2023, 24( 24): 17606. DOI: 10.3390/ijms242417606.
[43]	CAIRONI P, TOGNONI G, MASSON S, et al. Albumin replacement in patients with severe sepsis or septic shock[J]. N Engl J Med, 2014, 370( 15): 1412- 1421. DOI: 10.1056/NEJMoa1305727.
[44]	FINFER S, BELLOMO R, BOYCE N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit[J]. N Engl J Med, 2004, 350( 22): 2247- 2256. DOI: 10.1056/NEJMoa040232.
[45]	CHARPENTIER J, MIRA JP. Efficacy and tolerance of hyperoncotic albumin administration in septic shock patients: The EARSS study[J]. Intensive Care Med, 2011, 37: S115.
[46]	PHILIPS CA, MAIWALL R, SHARMA MK, et al. Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis(FRISC study): A randomized controlled trial[J]. Hepatol Int, 2021, 15( 4): 983- 994. DOI: 10.1007/s12072-021-10164-z.
[47]	PARK CHL, DE ALMEIDA JP, DE OLIVEIRA GQ, et al. Lactated Ringer’s versus 4% albumin on lactated Ringer’s in early sepsis therapy in cancer patients: A pilot single-center randomized trial[J]. Crit Care Med, 2019, 47( 10): e798- e805. DOI: 10.1097/CCM.0000000000003900.
[48]	GENG L, TIAN XX, GAO ZF, et al. Different concentrations of albumin versus crystalloid in patients with sepsis and septic shock: A meta-analysis of randomized clinical trials[J]. J Intensive Care Med, 2023, 38( 8): 679- 689. DOI: 10.1177/08850666231170778.
[49]	SHASTHRY SM, KUMAR M, KHUMUCKHAM JS, et al. Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion[J]. Liver Int, 2017, 37( 8): 1167- 1176. DOI: 10.1111/liv.13375.
[50]	JAGDISH RK, MARAS JS, SARIN SK. Albumin in advanced liver diseases: The good and bad of a drug![J]. Hepatology, 2021, 74( 5): 2848- 2862. DOI: 10.1002/hep.31836.
[51]	FORSTER CM, HALLS S, ALLARAKHIA S, et al. Improving appropriate use of intravenous albumin: Results of a single-centre audit and multifaceted intervention[J]. BMJ Open Qual, 2024, 13( 2): e002534. DOI: 10.1136/bmjoq-2023-002534.

Relative Articles

[1]	Lihong YANG, Jinhui YANG. Mechanism and treatment of portal-systemic circulatory imbalance in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(12): 2770-2773. doi: 10.3969/j.issn.1001-5256.2021.12.006
[2]	Qianmei CAO, Zhechuan MEI. Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(10): 2439-2443. doi: 10.3969/j.issn.1001-5256.2021.10.038
[3]	Jiaxuan HU, Tao HAN. An excerpt of diagnosis, evaluation, and management of ascites and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases[J]. Journal of Clinical Hepatology, 2021, 37(11): 2548-2549. doi: 10.3969/j.issn.1001-5256.2021.11.012
[4]	LI Yan, LU LunGen. Emphasis on the basic and clinical research on hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2401-2405. doi: 10.3969/j.issn.1001-5256.2020.11.001
[5]	LI Yan, LU LunGen, CAI XiaoBo. Advances in the treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2415-2418. doi: 10.3969/j.issn.1001-5256.2020.11.004
[6]	SONG JingRu, SUN MingYu. Research advances in integrated traditional Chinese and Western medicine therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2561-2564. doi: 10.3969/j.issn.1001-5256.2020.11.037
[7]	LI XiaoYun, HUA Jing. Treatment of hepatorenal syndrome:Vasoconstriction or vasodilation?[J]. Journal of Clinical Hepatology, 2020, 36(11): 2419-2422. doi: 10.3969/j.issn.1001-5256.2020.11.005
[8]	Tan YanXin, Long FuLi, Mao DeWen, Zhang JianLing, Ma YuZhen, Yan LianJie. Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2266-2271. doi: 10.3969/j.issn.1001-5256.2019.10.027
[9]	Yang Jun, Ning QiQi, Wu Jing, Li Juan, Zhu YueKe, Yu HongWei, Meng QingHua, Hu ZhongJie. Clinical effect of human serum albumin versus artificial colloidal fluid in patients with cirrhotic ascites undergoing drainage:A Meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(1): 82-86. doi: 10.3969/j.issn.1001-5256.2019.01.015
[10]	Chen LanLan, Han Wen, Liu JingJing, Hu Dan, He WeiWei. Research advances in the biomarkers for the early diagnosis of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2018, 34(11): 2448-2452. doi: 10.3969/j.issn.1001-5256.2018.11.040
[11]	Chen Li, Mei Yong, Yang YiBin, Cao MingYan. Research advances in renal replacement therapy for hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2016, 32(3): 605-608. doi: 10.3969/j.issn.1001-5256.2016.03.046
[12]	Zhan GuoQing, Li Fang, Li RuGui, Guo Peng, Liu Xiang, Zhang WeiWei, Tan HuaBing. Efficacy of terlipressin therapy for refractory ascites in cirrhosis and type-2 hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2015, 31(8): 1287-1290. doi: 10.3969/j.issn.1001-5256.2015.08.025
[13]	Chen Si, Sun ZhangYu, Zhang ZhiHao, Wang YingYing. Therapeutic effect of terlipressin combined with albumin in 24 patients with hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2014, 30(8): 782-784. doi: 10.3969/j.issn.1001-5256.2014.08.021
[14]	Xiao Qian, Zhang Yang, Tan ShanZhong. The treatment by warming the kidney and promoting diuresis with Alprostadil in liver cirrhosis complicated with hepato-renal syndrome in 29 cases[J]. Journal of Clinical Hepatology, 2012, 28(3): 189-191.
[15]	Wang JiYao. The difficulties in diagnosis and treatment of hepatorenal syndrome-raised by clinical cases[J]. Journal of Clinical Hepatology, 2011, 27(10): 1019-1021.
[16]	Xu XiaoYuan, Zheng YingYing. Hepatorenal syndrome-vasoconstrictor or vasodilator?[J]. Journal of Clinical Hepatology, 2011, 27(8): 801-803+817.
[17]	Zheng XiaoLi, Wang LiangZhi. Current diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(1): 107-109.
[18]	Xie YongPeng, Hou Yue, Zang XiuXian, Chu Zhe. The development of treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2011, 27(5): 558-561.
[19]	Fu Qiang, Tang TongYu. Advance in research of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2010, 26(5): 557-560.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (94) PDF downloads(23)

The application of human serum albumin in liver cirrhosis and its complications

DOI: 10.12449/JCH250303

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The application of human serum albumin in liver cirrhosis and its complications

DOI: 10.12449/JCH250303

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content